INmune Bio (INMB) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Supplement corrects a typographical error regarding the voting standard for Proposal 5 related to the Second Amended and Restated 2021 Stock Incentive Plan.
All other information and proposals in the original proxy statement remain unchanged.
Voting matters and shareholder proposals
Proposal 5 now requires the affirmative vote of the majority of shares cast on the proposal, not just those present in person or by proxy.
Abstentions and broker non-votes will count toward quorum but not as votes for or against Proposal 5.
Voting standards for Proposals 1–4 remain as previously stated.
Partial view of Summaries dataset, powered by Quartr API
Latest events from INmune Bio
- Net loss narrowed, cash reserves strong, but liquidity concerns persist amid regulatory progress.INMB
Q1 20267 May 2026 - Virtual meeting to elect directors, ratify auditor, and expand equity plan with evergreen provision.INMB
Proxy filing23 Apr 2026 - Late-stage clinical progress and regulatory filings drive 2026 outlook; cash runway through Q1 2027.INMB
Q4 202530 Mar 2026 - Late-stage therapies for RDEB and Alzheimer's advance toward 2026 filings, showing strong efficacy.INMB
Corporate presentation16 Mar 2026 - CORDStrom reduced itch and pain, improved healing, and showed strong safety in RDEB children.INMB
Study update26 Feb 2026 - Q2 net loss was $9.7M, $14.5M was raised, and $31.1M cash remains as clinical trials advance.INMB
Q2 20242 Feb 2026 - Alzheimer's and prostate cancer trials progress, net loss widens, key data expected in 2025.INMB
Q3 202417 Jan 2026 - Phase II Alzheimer's data and CORDStrom BLA filing set for 2025 amid robust R&D and financing.INMB
Q4 202425 Dec 2025 - Registering up to $250M in securities to fund immunology drug development amid ongoing losses.INMB
Registration Filing16 Dec 2025